title: Dexamethasone effects on the hospital course of infants with bronchopulmonary dysplasia who are dependent on artificial ventilation.
abstract: A randomized double-blind placebo-controlled trial was conducted to evaluate the effects of enterally administered dexamethasone on the hospital course of infants with bronchopulmonary dysplasia. A total of 23 infants with a birth weight less than 1500 g who were dependent on artificial ventilation 3 to 4 weeks of age received dexamethasone (n = 12) or saline placebo (n = 11). Dexamethasone (0.5 mg/kg per day) was given in tapering doses for 7 days followed by hydrocortisone (8 mg/kg per day) which was progressively reduced for a total of 17 days of therapy. Infants who received dexamethasone required less oxygen on days 8 and 17 (P less than .05) and were more likely to extubate 8 days after therapy than infants in the control group (respectively 8/12 vs 3/11 infants, P less than .05; P = .12 after Yates correction). The use of dexamethasone significantly shortened median duration of mechanical ventilation (4 vs 22 days, P less than .05) but had no effect on length of oxygen therapy, hospitalization, home oxygen therapy, occurrence and severity of retinopathy of prematurity, rate of growth, and mortality. No significant complications resulted from dexamethasone therapy. Measurements of plasma dexamethasone levels confirmed the absorption of drug from the gastrointestinal tract (23.7 ng/mL in dexamethasone vs 4.6 ng/mL in the control group, P less than .05). Dexamethasone administration resulted in short-term improvements in pulmonary function but did not ameliorate the hospital course of infants with bronchopulmonary dysplasia.
authors.affiliation: Department of Pediatrics, Hutzel Hospital, Wayne State University School of Medicine, Detroit, Michigan 48201.
authors.forename: N J
authors.initials: NJ
authors.lastname: Kazzi
authors.forename: Y W
authors.initials: YW
authors.lastname: Brans
authors.forename: R L
authors.initials: RL
authors.lastname: Poland
mesh_terms: D000284:Administration, Oral; D001997:Bronchopulmonary Dysplasia / Q000188:drug therapy* / Q000401:mortality / Q000628:therapy; D003907:Dexamethasone / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D004311:Double-Blind Method; D005260:Female; D006029:Glycosuria / Q000139:chemically induced; D006801:Humans; D006943:Hyperglycemia / Q000139:chemically induced; D006973:Hypertension / Q000139:chemically induced; D007231:Infant, Newborn; D007902:Length of Stay; D008297:Male; D010102:Oxygen Inhalation Therapy / Q000706:statistics & numerical data; D011446:Prospective Studies; D012121:Respiration, Artificial / Q000706:statistics & numerical data*; D018805:Sepsis / Q000139:chemically induced
chemical_list: D003907:Dexamethasone